G protein-coupled receptors (GPCRs) mediate transmembrane signaling. Before ligand binding, GPCRs exist in a basal state. Crystal structures of several GPCRs bound with antagonists or agonists have been solved. However, the crystal structure of the ligand-free basal state of a GPCR, the starting point of GPCR activation and function, had not yet been determined. Here we report the X-ray crystal structure of the ligand-free basal state of a GPCR in a lipid membrane-like environment.
GPCRs are transmembrane proteins that act as key gatekeepers between external signals and cellular responses 1, 2 . These receptors are activated by a diverse array of ligands, including photons, odorants, chemokines, hormones, growth factors and neurotransmitters. GPCRs have critical roles in regulating many physiological functions of eukaryotic cells 3 . They constitute the largest group of cell-surface receptors involved in signal transduction and have been one of the most important pharmaceutical drug targets 4, 5 . Both endogenous and exogenous substances can modulate the activity of GPCRs. An agonist increases the activity of its GPCR above the basal level, presumably through shifting GPCRs into an active state capable of interacting with downstream-signaling G proteins. An inverse agonist decreases the GPCR activity below its basal level, probably by stabilizing GPCRs in an inactive state uncoupled from G proteins. A neutral antagonist itself has no effect on the receptor's activity, but it can prevent the interaction of agonists or inverse agonists with GPCRs, although it does not affect the equilibria of different GPCR conformations 6 .
Crystal structures of several GPCRs have been determined [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Most of these GPCRs were bound with antagonists or agonists. No crystal structures of the ligand-free basal states of GPCRs have been determined, to our knowledge, except in the unusual case of rhodopsin 7 . Rhodopsin is a special case among GPCRs because, in its basal state, it is covalently bound with its inverse agonist cis-retinal. It is activated by photon absorption that isomerizes cis-retinal to the agonist all-trans-retinal 25 . Structural studies have shown that although the basal (inverse agonist-bound) rhodopsin adopts an inactive state, the ligand-free opsin has an active-state conformation 7, 12 . We set out to determine the crystal structure of a GPCR without ligands. Here we report the X-ray crystal structure of the β 1 -adrenergic receptor (β 1 -AR) in a ligand-free basal state.
In this structure, β 1 -AR forms oligomers in a lipid membrane-like environment and adopts an inactive-state conformation.
RESULTS

Structure determination
We determined the X-ray crystal structure of turkey β 1 -AR without ligands and in the presence of synthetic lipids ( Fig. 1, Table 1 and Supplementary Figs. 1 and 2) . Several complete data sets from individual crystals were recorded, and they gave similar structures. Only one representative data set from a single crystal is described here ( Table 1) . Diffraction of the crystal was highly anisotropic, and the structure was solved and refined at 3.5-Å resolution. The overall quality of the electron-density map was high. The structure of the ligand-free state of β 1 -AR was determined by molecular replacement using the partial agonist (salbutamol)-bound β 1 -AR as a search model 18 . Crystal packing indicated a membrane-like environment with extensive lipid impaction in one packing direction ( Fig. 1 and Supplementary Fig. 2a,b) . β 1 -AR packed as oligomers in parallel with two distinct dimer interfaces ( Fig. 1a-c) . Each crystallographic asymmetric unit had two β 1 -AR molecules (Supplementary Fig. 2c ). These two β 1 -AR molecules had similar configurations; the r.m.s. deviation was ~0.02 Å for all equivalent Cα atoms ( Supplementary Fig. 2d ). Although most of the experiments (including screening for crystallization conditions) described in this paper were done with the construct β 1 -AR(H0), the presented ligand-free structure was from the construct β 1 -AR(m23) because it gave a slightly higher resolution ( Supplementary Fig. 1 ). β 1 -AR(H0) contains deletions of amino acids 3-32, 249-283 and 366-483 and point mutations C116L and 358A (Supplementary Fig. 1 ). β 1 -AR(m23) is a thermostabilized β 1 -AR mutant that was used in previous crystal structural studies with antagonists or agonists 6, 7 .
A r t i c l e s
Receptor oligomerization: the TM1-TM2-H8 dimer interface
Within the same lipid bilayer, oligomers of β 1 -AR were packed in a parallel arrangement with two alternating dimer interfaces (Figs. 1b,c, 2 and 3). This oligomeric architecture was remarkably similar to the proposed models for oligomeric GPCRs based on a large body of functional data [26] [27] [28] [29] [30] [31] [32] [33] [34] . GPCRs can exist and function as dimers or oligomers [26] [27] [28] [29] 35 . Dimerization and oligomerization modulate various GPCR functions such as cell-surface targeting, cooperativity, activation, G-protein coupling, signaling and internalization 28, 29, 36 . In previous crystallographic studies with β 1 -AR bound with antagonists or agonists, β 1 -AR was observed as antiparallel dimers 10, 18 . The lack of oligomeric arrangement in those studies might be due to the exclusion of phospholipids in the crystallization conditions. Here, in one dimer interface (dimer interface 1), the interaction was mainly through TM1 as well as some residues from the C-terminal helical domain H8, TM2 and extracellular loop 1 (Figs. 1b,c and 2) . The total buried contact surface (from both protomers) was ~1,700 Å 2 ( Fig. 2a,b) . Interacting residues were mainly from TM1 (including Gln38, Gln39, Ala42, Leu46, Ala49, Leu50, Val52, Leu53 and Leu54; Fig. 2c ). Residues from other parts of the receptor also contributed to this dimer interface, including residues from TM2 (Pro96, Ala99, Thr100 and Val103; Fig. 2c ), extracellular loop 1 (Thr106, Leu108 and Trp109; Fig. 2c,d ) and the C-terminal H8 (Arg351, Lys354, Arg355 and Leu356; Fig. 2e ). In addition to these hydrophobic and van der Waals interactions, Ser45 in one TM1 formed a hydrogen bond with Ser45 from another TM1 (Fig. 2c) . Glu41 in TM1 from one monomer formed a salt bridge with Arg104 in TM2 from the second monomer ( Fig. 2c) . This dimer interface is similar to the one observed in the dimer of rhodopsin in the active state, which uses TM1 and H8 as an interface 12, 13 .
Receptor oligomerization: the TM4-TM5-ICL2 dimer interface
In the second dimer interface, the interacting regions involved residues from TM4, TM5, intracellular loop 2 (ICL2) and extracellular loop 2 (Figs. 1b,c and 3) . The total buried surface (from both receptors) was ~900 Å 2 (Fig. 3a,b) . Residues from both TM4 (including Leu171) and TM5 (including Arg205, Ala206, Ala210, Ile218 and Arg229) contributed to the hydrophobic interaction ( Fig. 3c,d) . ICL2 also had a critical role in this dimer interaction (including residues Tyr140, Leu141, Thr144, Ser145, Phe147, Arg148, Ser151 and Leu152; Fig. 3d ). Two residues (Trp181 and Arg183) from extracellular loop 2 also participated in this interaction ( Fig. 3c) . Previous studies, using the bioluminescence resonance energy transfer method, had shown that human β 1 -AR formed dimers and that TM4 was involved in their dimerization 37, 38 .
Disulfide trapping of b 1 -AR dimers
Next we used disulfide-trapping experiments to biochemically test some representative residues identified from our structural studies for their involvement in β 1 -AR dimerization in cells. Cysteine replacement of an appropriately disposed pair of residues at the dimer interfaces is expected to generate a disulfide bridge 30, 33, [39] [40] [41] . On the basis of our structural model, we selected a few residues from the two interfaces and mutated these residues into cysteines on the background of β 1 -AR(H0). In dimer interface 1, Lys354 from one protomer interacted with Lys354 from the second protomer ( Fig. 2e) . In dimer interface 2, Arg148 from one protomer interacted with Arg148 from the other 
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A r t i c l e s protomer ( Fig. 3d) . As a negative control, we also mutated Phe112 to cysteine. Phe112 is on the extracellular side of TM3 and was not involved in the dimer interfaces, on the basis of our crystal structure. We transfected these mutants individually into CHO cells, and stable cell lines were selected. After exposing the membrane preparations to the hyperoxidizing environment of copper phenanthroline (CuP), dimer formation was assessed by western blot analysis of detergentsolubilized protein samples with antibodies to β 1 -AR ( Fig. 3e) . Wildtype β 1 -AR (having no cysteine residues in the two dimer interfaces) and the F112C mutant showed only monomers with or without CuP
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A r t i c l e s treatment ( Fig. 3e) . Mutants R148C and K354C showed increased formation of dimers after CuP treatment ( Fig. 3e) . R148C mutants formed some dimers without CuP treatment, probably as the result of air oxidation, as shown for some cysteine mutants of serotonin 5HT2c receptors 41 . These data confirm that the two dimer interfaces identified in our structure form under physiological conditions. Hence, our crystal structure provides a structural context for the dimerization and oligomerization of GPCRs and the coexistence of the two types of dimers within the oligomers.
Ligand-free basal state of b 1 -AR in an inactive conformation
One of the characteristics of the inactive state of class A GPCRs is the presence of the ionic-lock salt bridge between the highly conserved D(E)R 3.50 Y motif in TM3 and an E/D 6.30 residue in TM6 (Ballesteros-Weinstein numbering system is in superscripts) 7, 14, 16, 42 . This ionic-lock salt bridge between Arg139 3.50 and Glu285 6.30 was present in the ligand-free state of β 1 -AR ( Fig. 4a,b) . Hence, our data are consistent with the ligand-free basal-state β 1 -AR being in an inactive state.
In the first report of the crystal structure of β 1 -AR bound with the antagonist cyanopindolol, the ionic lock was absent 10 . In a subsequent report of the crystal structures of β 1 -AR with cyanopindolol, the ionic lock was present in some structures but absent in others 43 . In the structure of cyanopindolol-bound β 1 -AR with the ionic lock, the cytoplasmic end of TM6 (the G protein-interacting region) was in a bent conformation ( Fig. 4c) 43 . In the cyanopindolol-bound β 1 -AR without the ionic lock, the cytoplasmic end of TM6 was in a straight conformation ( Fig. 4d) 43 . Thus, it was proposed that the presence of the ionic lock was associated with the bent conformation of the cytoplasmic end of TM6 (ref. 43) . However, in the ligand-free basal-state structure of β 1 -AR described here, the ionic lock existed concomitantly with the straight conformation of TM6 ( Fig. 4c,d) .
The basal state with a contracted ligand-binding pocket
On the basis of comparisons of the crystal structures of several GPCRs in inactive and active states, it has been proposed that, although the overall GPCR structures did not change significantly, an outward movement of the cytoplasmic end of TM6 (and, to a lesser degree, TM5 as well) relative to the receptor helix-bundle core is a hallmark of the active state 13, 17, [22] [23] [24] . The ligand-free basal state of β 1 -AR did not display this characteristic outward movement of TM6 and TM5, consistent with its inactive conformation. Furthermore, agonist binding 
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A r t i c l e s to β 1 -AR induces the contraction of the ligand-binding pocket by ~1 Å (as measured between the Cα atoms of Ser211 and Asn329) 18 .
The ligand-binding pocket in the ligand-free state of β 1 -AR was empty ( Fig. 4e and Supplementary Fig. 3) . Moreover, the ligand-binding pocket of the ligand-free state of β 1 -AR was narrower than that of the antagonist-bound structure and was similar to that of the agonistbound structure of β 1 -AR ( Fig. 4f-h) . Thus, the contraction of the ligand-binding pocket may not be an essential feature of the binding of full agonists to β 1 -AR.
DISCUSSION
The ligand-free basal state of GPCRs Before ligand binding, GPCRs are in a basal state. As agonists or inverse agonists could shift the ligand-free state to an activated state or an inactive state, respectively, the ligand-free state is probably conformationally flexible. This may partly explain the difficulty in crystallizing ligand-free GPCRs. However, many GPCRs, including β 1 -AR, have a low basal activity in the absence of ligands, which suggests that, in the ligand-free state, a large fraction of the receptor population is in the inactive state. For the ligand-free GPCRs, although opsin is in an active state, the ligand-free β 1 -AR is in an inactive state. These differences might reflect the different crystallization conditions such as the presence of membrane-like environment in the β 1 -AR structure or different stabilized conformations caused by different crystal packings. The crystal structures only provide a snapshot of the lowest-energy conformations that these receptors could adopt under the specific crystallization conditions. It might also be argued that the ligand-free β 1 -AR observed here in the inactive state was stabilized by the thermostabilizing mutations. However, that is unlikely because these thermostabilizing mutations, although making β 1 -AR proteins more stable at higher temperatures, do not stabilize β 1 -AR(m23) in an inactive conformation. As recently reported, this mutated β 1 -AR(m23) is still a functional receptor capable of binding agonists and antagonists and activating intracellular agonist responses (Supplementary Fig. 4; ref. 44 ). Furthermore, most crystal structures of this thermostabilized β 1 -AR(m23) with agonists or antagonists displayed intermediate conformations without the ionic lock and without the outward movement of the cytoplasmic end of TM6 (refs. 10, 18, 43) . The structure presented here was determined from β 1 -AR proteins purified with alprenolol-affinity purification (eluted with cyanopindolol) as the second purification step. Although the protein samples were dialyzed with buffers without cyanopindolol, and the crystallization condition was at ~pH 4, which reduced antagonist binding to β 1 -AR ( Supplementary Fig. 4) , we could not completely exclude the possibility of a very low occupancy of cyanopindolol in the presented structure. However, use of β 1 -AR proteins purified with two rounds of nickel-affinity purifications (without the alprenololaffinity purification step) resulted in similar structures, although at lower resolutions.
It is known that some GPCRs display varying levels of constitutive activity (that is, the basal activity in the absence of any ligands), which are critical for their physiological functions. Structural determinations of the ligand-free states of these GPCRs should provide molecular insights into the activation processes of GPCRs, the basal activities and the development of agents for therapeutic applications, as the ligandfree state is the starting state and offers a point of comparison.
Dimer interfaces and G-protein interaction
In our crystal structure of β 1 -AR oligomers, there are two dimer interfaces: one involves TM1-TM2-H8, and the other engages TM4-TM5-ICL2 (Fig. 1) . Among the published crystal structures of GPCRs, there are four other GPCRs showing parallel dimers. In rhodopsin and κ-opioid receptor, the dimer interface involves residues from TM1-TM2-H8 (refs. 12,13,45,46 ; Supplementary Fig. 5a,b) . This dimer interface is similar to dimer interface 1 in our β 1 -AR structure. In the CXCR4 structure, there is a dimer interface involving residues from TM5 and TM6 (ref. 15; Supplementary Fig. 5c ). However, dimer interface 2 of β 1 -AR involves TM4 and TM5. Compared to β 1 -AR, one monomer of CXCR4 rotates ~40° toward another monomer (Supplementary Fig. 5c ). In a recent crystal structure of oligomeric µ-opioid receptor, two dimer interfaces were observed: one involves TM1-TM2-H8, and the other involves TM5-TM6 (ref. 47 ). Hence, the TM1-TM2-H8 interface is rather conserved in various GPCRs. In contrast, the TM5 interface sometimes functions with TM4 and other times with TM6. Notably, the crystal structures of GPCRs so far only displayed these two types of dimer interfaces, which are in agreement with a large body of experimental data, indicating that these two dimer interfaces are likely to be physiological relevant.
In addition to the TMs, intracellular regions contribute significantly to the dimer interfaces. There are four residues from H8 involved in the TM1-TM2-H8 dimer interface. Eight residues from ICL2 contribute to the TM4-TM5-ILC2 dimer interface. ICL2 is critical for interacting with G proteins on the basis of the structural model of the complex of β 2 -AR and G s (ref. 24) . A G s trimer could be docked onto a β 1 -AR dimer formed through the TM1-TM2-H8 dimer interface (Fig. 5a,b) . However, it was not possible to dock a G s trimer onto the β 1 -AR dimer formed by the TM4-TM5-ICL2 dimer 
npg
A r t i c l e s interface without steric collisions (Fig. 5c,d) . Participation of ICL2 in this dimer interface may prevent G-protein coupling to the dimer formed through the TM4-TM5-ICL2 interface, or G-protein binding may disrupt this dimer interface. Therefore, we propose that, if the signaling unit is a pentamer (two GPCRs and one trimeric G protein), the GPCR dimer interface in this signaling unit is TM1-TM2-H8 (Fig. 5a,b ). In this model, only one β 1 -AR contacts the G-protein trimer, and the other β 1 -AR is 'spared' or could function through trans-protomer allosteric regulation (discussed below).
GPCR oligomerization and receptor activation
In our crystal structure, β 1 -AR forms oligomers in a membrane-like environment. Although the physiological functions are not clear, studies using various approaches have indicated that GPCRs could form oligomers in cells 28, 29, 34, 48, 49 . While our manuscript was under review, a recent crystal structure of µ-opioid receptor also showed oligomers 47 . The β 1 -AR oligomers show some similarities and some differences from the oligomers of µ-opioid receptors (Fig. 6a) . Both oligomers have two dimer interfaces and share the same TM1-TM2-H8 dimer interface (Fig. 6a) . However, in the second dimer interface, TM5 works together with TM4 in β 1 -AR, whereas TM5 acts together with TM6 in µ-opioid receptors (Fig. 6a) . Furthermore, β 1 -AR oligomers form a linear array in one direction, but µ-opioid receptors are in a sine-wave arrangement (Fig. 6a) .
A docking exercise revealed that with the oligomeric arrangement, trimeric G proteins could not be fitted in without steric hindrance (Supplementary Fig. 6 ). Even though this docking was speculative, it suggests that either G-protein binding may disrupt the oligomers or change the oligomeric arrangement, or the oligomeric architecture would prevent the pronounced sideways rotation and upward translation of the helical domain of the Gα s subunit relative to the Ras-like domain of the Gα s subunit, as observed in the crystal structure of the complex of β 2 -AR and G s 24 . Indeed, the extent of membrane-driven oligomerization of a GPCR (such as D2 receptors and 5HT2c receptors) in the inverse agonist-bound state may be larger than in the agonist-bound state 40, 41 . Moreover, inverse agonists stabilize β 2 -AR oligomers, whereas G s reduced the extent of oligomerization of β 2 -AR 50 . Hence oligomerization of GPCRs is sensitive to ligand binding. That is, agonist binding may disrupt the oligomerization of GPCRs into dimers and/or tetramers.
It is possible to dock two trimeric G proteins into a β 1 -AR tetramer (Fig. 6b) . To know whether this model is physiologically relevant requires further experimental testing. In this model, the two protomers through the TM4-TM5-ICL2 dimer interface were spared (not interacting with G proteins; Fig. 6b ). An asymmetric function for GPCR dimers has been proposed 34, 51 . Previously, a dimer interface involving TM1 has been shown to be insensitive to ligand binding and the receptor-activation state, as shown for dopamine D2 receptors and serotonin 5HT2c receptors 31, 41 . The similarity of dimer interface 1 (involving TM1) in the inactive β 1 -AR and the active rhodopsin is consistent with the notion that this dimer interface involving TM1 does not undergo significant conformational changes from inactive to active states of GPCRs ( Supplementary Fig. 5a ). In contrast, the dimer interface involving TM4 makes structural rearrangements during the GPCR activation process, at least in the cases of dopamine D2 receptors and serotonin 5HT2c receptors 40, 41 . These imply a possible role for the TM4-TM5 dimer interface in GPCR transactivation, even though the two promoters do not directly interact with G proteins in the proposed model ( Fig. 6b) . On the basis of the structures of active GPCRs, the intracellular end of TM5 moves away from the TM bundle core 24 . Therefore it is possible that, upon the agonist's binding, the configuration change at the TM4-TM5 dimer interface is part of the receptor-activation process.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Atomic coordinates and structure factor files for the oligomeric turkey β 1 -AR have been deposited in the PDB, with accession number 4GPO.
Note: Supplementary information is available in the online version of the paper. npg ONLINE METHODS b 1 -AR constructs and purification of b 1 -AR proteins. A cDNA plasmid for the turkey β 1 -AR was obtained from E. Ross 52 . For precrystallization screening of β 1 -AR constructs for structural studies, we used the fluorescence-detection size-exclusion chromatography (FSEC) method for integral membrane proteins developed previously 53 . In this screening method, the target proteins are covalently fused to GFP. The resultant fusion proteins are monitored first for expression level and pattern in whole cells by epifluorescence microscopy. After solubilization of whole cells or crude membranes, the resulting unpurified protein is analyzed by FSEC. A monodispersed and folded protein would generally yield a single symmetrical Gaussian peak, whereas a polydispersed, unstable or unfolded protein would typically yield multiple asymmetric peaks 53 . We PCR subcloned different β 1 -AR constructs into the pCGFP vector (from O. Boudker and E. Gouaux) and transfected them into HEK 293 cells. On the basis of previous studies with many different GPCRs, we focused on deletions on the N terminus, the C terminus and the intracellular-loop-3 region of β 1 -AR. Two days after transfection, the subcellular localizations of the β 1 -AR receptors were checked by fluorescence microscopy. All tested constructs expressed proteins at the plasma membrane. Membrane preparations were solubilized in a buffer containing the nonionic detergent n-dodecyl-β-d-maltoside (DDM), and the resulting supernatant was analyzed by FSEC. Among the ~40 β 1 -AR constructs, several β 1 -AR constructs displayed a nearly symmetric fluorescence peak with an apparent molecular weight of a monomer of β 1 -AR in DDM (the protein-detergent complex; Supplementary Fig. 7a) . We purified the recombinant β 1 -AR proteins from High5 insect cells. The stability of these β 1 -AR proteins in different detergents was tested at 18 °C. Most of the studies were with a β 1 -AR construct (β 1 -AR(H0)) with deletions of amino acids 3-32, 249-283 and 366-483 and point mutations C116L and C358A (Supplementary Fig. 1 ). β 1 -AR(H0) generated similar cAMP responses as did wild-type β 1 -AR when expressed in β 1 -AR −/− ;β 2 -AR −/− MEF cells 54 (Supplementary Fig. 7b ). β 1 -AR mutants (with a C-terminal His 6 tag) were subcloned into baculoviral expression vector pVL1393. Recombinant baculoviruses were picked and amplified. High5 insect cells were grown in suspension in High5 Express Medium (Invitrogen) at 27 °C with shaking at 110 r.p.m. Cells were infected at a multiplicity of infection of 5-10. Following shaking for one hour, an equal volume of fresh medium was added. Cells were harvested by centrifugation 48 h after infection. Infected cells from cultures were harvested by centrifugation, and the resulting pellet was resuspended in 20 mM Tris-HCl, pH 8, 1 mM EDTA. Cells were flash frozen in liquid nitrogen and stored at −80 °C. Cells were broken by sonication. After centrifugation at 2,000 r.p.m. for 10 min, the supernatant was collected and centrifuged for 1 h at 45,000 r.p.m. at 4 °C in a Beckman Ti45 rotor. Membrane pellets were resuspended in the same volume of buffer, and the centrifugation was repeated. The final pellet was resuspended in a buffer with a reduced EDTA concentration (0.2 mM) at 10-20 mg protein/ml and frozen in liquid nitrogen and stored at −80 °C. Membranes containing 2 g of total proteins were thawed and diluted to 10 mg/ml protein in ice-cold 20 mM Tris-HCl, pH 8, with 0.35 M NaCl, 2% DDM and protease inhibitors and then stirred at 4 °C for 1 h. After centrifugation for 1 h at 45,000 r.p.m. in a Ti45 rotor (4 °C), solubilized membrane proteins were mixed with Ni-NTA beads preequilibrated with buffer A (20 mM Tris-HCl, pH 8, 0.35 M NaCl, 10 mM imidazole, protease inhibitors and 0.025% DDM). The mixture was rolled at 4 °C for 6 h. The protein-loaded resin was washed with buffer B (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 0.025% DDM), and the bound protein was eluted by using 3× bed volume buffer C (20 mM Tris-HCl, pH 8.0, 50 mM NaCl, 250 mM imidazole, 0.025% DDM). In some preparations, β 1 -AR proteins were purified again with a second round of Ni-NTA affinity purification and used for crystallization. In other preparations, β 1 -AR proteins were purified by alprenolol-affinity purification. For alprenolol-affinity purification, after dilution of the protein sample with four volumes of buffer D (Buffer C without imidazole), the sample was incubated with alprenolol-Affi-Gel beads overnight at 4 °C. Alprenolol-NH 2 was synthesized at Cornell's chemistry core facility, following a published protocol 55 . Alprenolol was cross-linked to Affi-Gel-15. After the alprenolol beads were washed with buffer D, β 1 -AR was eluted with buffer D containing 50 µM cyanopindolol and then dialyzed, concentrated and changed to a buffer of 10 mM Tris, pH 7.7, 50 mM NaCl, 0.02% DDM and 0.1 mM EDTA with Centricons (100 kDa cutoff; Millipore) 56, 57 . SDS-PAGE showed that β 1 -AR protein was >90% pure. The yield was ~2 mg of purified β 1 -AR proteins from 1 l of insect cells.
Crystallization. β1-AR(H0) proteins were initially used for screening crystallization conditions. β 1 -AR at a final concentration of ~8 mg/ml in 20 mM Tris-HCl, pH 7.7, 50 mM NaCl, 0.1 mM EDTA, 0.02% DDM, 0.1 mg/ml lipid (3:1:1:1 POPC/POPE/POPG/cholesterol) was incubated on ice for 1 h before setup of the tray. Crystals were obtained in several crystallization conditions. To further ensure that there were no ligands in the final crystals, we selected conditions with low pH, which decreased the binding of ligands from β1-AR 58 (Supplementary  Fig. 4) . Crystallization was performed by the vapor-diffusion hanging-drop method at 18 °C. A volume of 1 µl β 1 -AR protein sample was mixed with 1 µl crystallization buffer (0.1-0.3 M (NH 4 ) 2 SO 4 , 0.02 M NaAc, pH 3.6-4, 26-30% PEG 200). With the β 1 -AR(H0) construct, the screened crystals yielded diffraction to ~8 Å. We then introduced the six point mutations (R68S, M90V, Y227A, A282L, F327A and F338M) and generated a construct the same as the thermostabilized β 1 -AR(m23) (Supplementary Fig. 1) 18 . Thus the ligand-free structure described here was for β 1 -AR(m23), and this thermostabilized β 1 -AR mutant was used in previous crystal structural studies with antagonists or agonists 10, 18 . This mutant β 1 -AR is able to adopt different conformations, to bind antagonists, partial agonists and agonists, as well as to activate G proteins and increase cAMP levels in cells in response to agonists 10, 18, 44 . Crystals were formed within one week and were directly frozen in liquid nitrogen. Crystals were screened, and diffraction data were collected at the National Synchrotron Light Source (beamlines X6A and X25) of the Brookhaven National Laboratory or the Advanced Photon Source beamline NE-CAT 24E at Argonne National Laboratory.
